At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 120 enrolled
Drug / intervention
Netarsudil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
In Brief
A Phase 3 clinical trial evaluating Netarsudil and Placebo for Fuchs' Endothelial Dystrophy and Bullous Keratopathy. Completed, enrolled 120 participants across 1 site.
Detailed Summary
Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFuchs' Endothelial Dystrophy, Bullous Keratopathy
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionJul 2019
TodayJul 2026
First PostedAug 14, 2017
Enrollment StartSep 5, 2017
Primary CompletionJul 9, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.9 years ago
Interventions
Netarsudildrug
netarsudil opthalmic solution 0.02%
Placebodrug
Placebo eye drops